{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:49:20Z","timestamp":1793627360634,"version":"4.5.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.transci.2008.05.009","type":"journal-article","created":{"date-parts":[[2008,6,26]],"date-time":"2008-06-26T05:10:33Z","timestamp":1214457033000},"page":"45-48","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic plasma exchange in Casablanca"],"prefix":"10.1016","volume":"39","author":[{"given":"I.","family":"Tazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Merimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Benchemsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2008.05.009_bib1","doi-asserted-by":"crossref","unstructured":"Editorial. Current status of therapeutic apheresis in Japan: is it a better example for worldwide clinical apheresis? Ther Apher 1998;2:171.","DOI":"10.1111\/j.1744-9987.1998.tb00099.x"},{"key":"10.1016\/j.transci.2008.05.009_bib2","doi-asserted-by":"crossref","unstructured":"Editorial. Therapeutic apheresis in the United States: current indications and directions. Ther Apher 1999;3:1\u20133.","DOI":"10.1046\/j.1526-0968.1999.0148m.x"},{"key":"10.1016\/j.transci.2008.05.009_bib3","first-page":"4","article-title":"Overview of therapeutic apheresis in the USA","volume":"3","author":"Koo","year":"1999","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2008.05.009_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1473-0502(01)00079-9","article-title":"Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry","volume":"25","author":"Norda","year":"2001","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.transci.2008.05.009_bib5","unstructured":"Arslan O. XXVI. National Hematology Congress of Scientific Meeting Speaking: Therapeutic Plasma Exchange 1998, November 1998, Ankara. p. 197\u2013203."},{"key":"10.1016\/j.transci.2008.05.009_bib6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM198403223101206","article-title":"Therapeutic plasma exchange","volume":"310","author":"Shumak","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2008.05.009_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Eng J Med"},{"key":"10.1016\/j.transci.2008.05.009_bib8","first-page":"210","article-title":"Highly substituted HES leads to Type I Von Willebrand Syndrome after repeated administration","volume":"26","author":"Treib","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.transci.2008.05.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-1101(2000)15:1\/2<1::AID-JCA1>3.0.CO;2-R","article-title":"Introduction to the third special issue: clinical applications of therapeutic apheresis","volume":"15","author":"McLeod","year":"2000","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.transci.2008.05.009_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jca.2920070202","article-title":"Canadian Apheresis Group. Therapeutic apheresis in Canada","volume":"7","author":"Rock","year":"1992","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.transci.2008.05.009_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0955-3886(95)00039-9","article-title":"The national survey of plasma exchange and therapeutic apheresis in France","volume":"16","author":"Korach","year":"1995","journal-title":"Transfus Sci"},{"key":"10.1016\/j.transci.2008.05.009_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1526-0968.2002.00401.x","article-title":"Apheresis in the treatment of the inflammatory demyelinating peripheral neuropathies","volume":"6","author":"Kincaid","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2008.05.009_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: an update from the Canadian Apheresis Group","author":"Clark","year":"1999","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.transci.2008.05.009_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jca.20038","article-title":"Apheresis in the Philippines","volume":"20","author":"Narciso","year":"2005","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.transci.2008.05.009_bib15","series-title":"Therapeutic Hemapheresis in 1990s","first-page":"10","article-title":"The risk\/benefit equation for therapeutic plasma exchange","author":"Isbister","year":"1990"},{"key":"10.1016\/j.transci.2008.05.009_bib16","series-title":"Current Status of Hemapheresis: Indications, Technology and Complications","first-page":"87","article-title":"Complications of hemapheresis","author":"Westphal","year":"1987"},{"key":"10.1016\/j.transci.2008.05.009_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0955-3886(99)00042-9","article-title":"The Canadian Apheresis Group and therapeutic plasma exchange","volume":"20","author":"Rock","year":"1999","journal-title":"Transfus Sci"},{"key":"10.1016\/j.transci.2008.05.009_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-0502(01)00090-8","article-title":"14 years of therapeutic plasma exchange in France","volume":"25","author":"Korach","year":"2001","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.transci.2008.05.009_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1526-0968.2001.00336.x","article-title":"Apheresis technologies and clinical applications: the 2000 International Apheresis Registry","volume":"5","author":"Malchesky","year":"2001","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2008.05.009_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0955-3886(00)00132-6","article-title":"Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis Study Group","volume":"24","author":"Norda","year":"2001","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2008.05.009_bib21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s001340050595","article-title":"Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group","volume":"24","author":"Korach","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.transci.2008.05.009_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: complications and management","volume":"23","author":"Mokrzycki","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2008.05.009_bib23","series-title":"Therapeutic Plasma Exchange","article-title":"Problems of plasma exchange therapy","author":"Borberg","year":"1980"},{"key":"10.1016\/j.transci.2008.05.009_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1526-0968.2003.00111.x","article-title":"Current status of therapeutic plasma exchange in Korea","volume":"8","author":"Song","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2008.05.009_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"1","author":"Ring","year":"1977","journal-title":"Lancet"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050208000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050208000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T06:13:17Z","timestamp":1557641597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050208000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S1473050208000839"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2008.05.009","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}